Results of Ivosidenib (inhibitor of mutant IDH1) for nonenhancing IDH1 mutant gliomas

Just published in the Journal of Clinical Oncology

Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
https://sci-hub.tw/10.1200/JCO.19.03327

• out of 35 patients with nonenhancing glioma, objective response rate was 2.9% with one partial response
• of these same patients, 30/35 (85.7%) had stabilization of their disease.
• for these same 35 patients, median progression-free survival was 13.6 months.
• the drug was well-tolerated with no dose-limiting toxicities reported.

As seen here, many of the patients with non-enhancing glioma have had disease stabilization for three years or more.  Not bad for a drug that is so well tolerated and with no dose-limited toxicities.